

Pierre Marquet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1291893/publications.pdf>

Version: 2024-02-01

219
papers

8,837
citations

36271

51
h-index

62565

80
g-index

234
all docs

234
docs citations

234
times ranked

6606
citing authors

#	ARTICLE	IF	CITATIONS
1	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	1.0	398
2	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	1.0	374
3	IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM. <i>Drug Metabolism and Disposition</i> , 2005, 33, 139-146.	1.7	251
4	Mechanisms Underlying Postmortem Redistribution of Drugs: A Review. <i>Journal of Analytical Toxicology</i> , 2003, 27, 533-544.	1.7	243
5	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	2.3	171
6	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2628-2640.	1.3	141
7	Screening of Drugs and Toxic Compounds with Liquid Chromatography-Linear Ion Trap Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2006, 52, 1735-1742.	1.5	132
8	IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 689-695.	1.7	129
9	Progress of Liquid Chromatography-Mass Spectrometry in Clinical and Forensic Toxicology. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 255-276.	1.0	122
10	Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 805-816.	1.6	117
11	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. <i>Transplantation Reviews</i> , 2011, 25, 47-57.	1.2	116
12	Current role of LC-MS in therapeutic drug monitoring. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 1327-1349.	1.9	105
13	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	1.0	102
14	Pesticide contamination of workers in vineyards in France. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2006, 16, 115-124.	1.8	100
15	Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2004, 43, 253-266.	1.6	99
16	Pitfalls and Prevention Strategies for Liquid Chromatography-Tandem Mass Spectrometry in the Selected Reaction-Monitoring Mode for Drug Analysis. <i>Clinical Chemistry</i> , 2008, 54, 1519-1527.	1.5	97
17	Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 354-361.	1.0	96
18	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 170-189.	1.0	95

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations â€“ twice daily Prograf [®] and once daily Advagraf [®] . <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 391-402.	1.1	93
20	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 51-60.	2.3	91
21	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	1.0	89
22	Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 253-262.	1.0	87
23	LC-MS/MS systematic toxicological analysis: Comparison of MS/MS spectra obtained with different instruments and settings. <i>Clinical Biochemistry</i> , 2005, 38, 362-372.	0.8	86
24	Buprenorphine withdrawal syndrome in a newborn. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 569-571.	2.3	85
25	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
26	Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2010, 38, 40-45.	1.7	84
27	Applications of Liquid Chromatography-Mass Spectrometry in Analytical Toxicology: A Review. <i>Journal of Analytical Toxicology</i> , 1997, 21, 116-126.	1.7	83
28	Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 609-619.	1.0	82
29	Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation. <i>Clinical Pharmacokinetics</i> , 2010, 49, 683-692.	1.6	81
30	Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. <i>Hepatology</i> , 2008, 47, 1453-1461.	3.6	80
31	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	1.0	78
32	Evaluation of an improved general unknown screening procedure using liquid-chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatographyâ€”diode array detection. <i>Journal of the American Society for Mass Spectrometry</i> , 2003, 14, 14-22.	1.2	75
33	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019, 46, 463-472.	2.7	75
34	Sensitive and specific multiresidue methods for the determination of pesticides of various classes in clinical and forensic toxicology. <i>Forensic Science International</i> , 2001, 121, 116-125.	1.3	74
35	Involvement of UDP-Glucuronosyltransferases UGT1A9 and UGT2B7 in Ethanol Glucuronidation, and Interactions with Common Drugs of Abuse. <i>Drug Metabolism and Disposition</i> , 2013, 41, 568-574.	1.7	73
36	Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 805-811.	0.8	71

#	ARTICLE	IF	CITATIONS
37	Establishing Biomarkers in Transplant Medicine. <i>Transplantation</i> , 2016, 100, 2024-2038.	0.5	71
38	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 321-330.	0.7	68
39	Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 600-608.	1.0	65
40	Is LC-MS Suitable for a Comprehensive Screening of Drugs and Poisons in Clinical Toxicology?. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 125-133.	1.0	64
41	Liquid Chromatography-Tandem Mass Spectrometry for Detection of Low Concentrations of 21 Benzodiazepines, Metabolites, and Analogs in Urine: Method with Forensic Applications. <i>Clinical Chemistry</i> , 2006, 52, 1346-1355.	1.5	64
42	Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1135-1148.	1.6	63
43	Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation. <i>Clinical Pharmacokinetics</i> , 2012, 51, 175-186.	1.6	61
44	A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil. <i>Clinical Pharmacokinetics</i> , 2005, 44, 837-847.	1.6	59
45	CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients. <i>Transplantation</i> , 2011, 91, 652-656.	0.5	59
46	Uterus retrieval process from brain dead donors. <i>Fertility and Sterility</i> , 2014, 102, 476-482.	0.5	59
47	Determination of Buprenorphine and Norbuprenorphine in Whole Blood by Liquid Chromatography-Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 1997, 21, 160-165.	1.7	58
48	Lessons From Routine Dose Adjustment of Tacrolimus in Renal Transplant Patients Based on Global Exposure. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 322-327.	1.0	58
49	HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. <i>Liver International</i> , 2015, 35, 2222-2227.	1.9	58
50	Ribavirin: Past, present and future. <i>World Journal of Hepatology</i> , 2016, 8, 123.	0.8	56
51	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2009, 48, 419-462.	1.6	55
52	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S57-S69.	1.0	54
53	Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal Transplants. <i>Clinical Pharmacokinetics</i> , 2002, 41, 71-80.	1.6	53
54	Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Cyclosporin or Sirolimus. <i>Clinical Pharmacokinetics</i> , 2009, 48, 745-758.	1.6	52

#	ARTICLE	IF	CITATIONS
55	QuEChERS sample preparation prior to LC-MS/MS determination of opiates, amphetamines, and cocaine metabolites in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 1467-1474.	1.9	52
56	Application of a Gamma Model of Absorption to Oral Cyclosporin. <i>Clinical Pharmacokinetics</i> , 2001, 40, 375-382.	1.6	51
57	Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1317-1328.	1.6	50
58	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 718-724.	1.0	50
59	In silico pharmacology: Drug membrane partitioning and crossing. <i>Pharmacological Research</i> , 2016, 111, 471-486.	3.1	50
60	A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 477-484.	1.1	48
61	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. <i>Clinical Pharmacokinetics</i> , 2008, 47, 277-284.	1.6	48
62	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 537-543.	0.7	48
63	Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 169, 210-218.	1.2	48
64	Adaptive Control Methods for the Dose Individualisation of Anticancer Agents. <i>Clinical Pharmacokinetics</i> , 2000, 38, 315-353.	1.6	47
65	Relationship between Psychotropic Drugs and Thyroid Function: A Review. <i>Toxicology and Applied Pharmacology</i> , 1998, 149, 127-135.	1.3	46
66	Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 274-277.	1.0	46
67	General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: Applications and constraints. <i>Journal of Separation Science</i> , 2009, 32, 3074-3083.	1.3	46
68	Tacrolimus Exposure Prediction Using Machine Learning. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 361-369.	2.3	45
69	Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. <i>Pharmacological Research</i> , 2011, 63, 423-431.	3.1	44
70	Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 285-294.	1.0	44
71	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. <i>Frontiers in Pharmacology</i> , 2017, 8, 358.	1.6	44
72	Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 867-876.	1.1	42

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 129-135.	1.0	42
74	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the <i>UGT1A8*2</i> variant allele. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 675-683.	1.1	40
75	Analytical Findings in a Suicide Involving Sodium Azide. <i>Journal of Analytical Toxicology</i> , 1996, 20, 134-138.	1.7	39
76	Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions. <i>American Journal of Transplantation</i> , 2005, 5, 1477-1482.	2.6	39
77	Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5. <i>Drug Metabolism and Disposition</i> , 2007, 35, 350-355.	1.7	39
78	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , 2015, 16, 1119-1134.	0.6	39
79	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1491-1498.	1.6	39
80	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II. <i>Clinical Pharmacokinetics</i> , 2009, 48, 489-516.	1.6	38
81	Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 214, 162-167.	0.5	38
82	Screening of pesticides in blood with liquid chromatography-linear ion trap mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2235-2249.	1.9	37
83	A Non-fatal Case of Intoxication with Foxglove, Documented by Means of Liquid Chromatography-Electrospray-Mass Spectrometry. <i>Journal of Forensic Sciences</i> , 2000, 45, 1154-1158.	0.9	37
84	Rheumatoid Factor Interference in a Tacrolimus Immunoassay. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 743-745.	1.0	35
85	Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1777-1782.	2.2	35
86	Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised Osteosarcoma. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1095-1104.	1.6	34
87	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 731-743.	1.5	34
88	Advagraf [®] , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. <i>Transplant International</i> , 2016, 29, 860-869.	0.8	34
89	Adherence profiles in kidney transplant patients: Causes and consequences. <i>Patient Education and Counseling</i> , 2020, 103, 189-198.	1.0	34
90	Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. <i>Transplant International</i> , 2010, 23, 227-230.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Tungsten Determination in Biological Fluids, Hair and Nails by Plasma Emission Spectrometry in a Case of Severe Acute Intoxication in Man. <i>Journal of Forensic Sciences</i> , 1997, 42, 527-530.	0.9	33
92	Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. <i>Transplantation</i> , 2003, 76, 683-688.	0.5	32
93	Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between <i>SLCO1B1</i> SNPs and Methotrexate Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 687-698.	2.3	32
94	Simultaneous determination of amphetamine and its analogs in human whole blood by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , 1997, 700, 77-82.	1.7	31
95	Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 34-42.	2.3	31
96	Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase. <i>Clinical Chemistry</i> , 2009, 55, 986-993.	1.5	31
97	Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. <i>Pharmacological Research</i> , 2011, 63, 1-7.	3.1	31
98	Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry. <i>Biomedical Applications</i> , 1997, 692, 329-335.	1.7	30
99	Identification and Quantitation of Six Non-Depolarizing Neuromuscular Blocking Agents by LC-MS in Biological Fluids. <i>Journal of Analytical Toxicology</i> , 2004, 28, 105-110.	1.7	30
100	Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2009, 48, 667-675.	1.6	30
101	Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on Sirolimus In Vitro Metabolism and Trough Concentrations in Kidney Transplant Recipients. <i>Clinical Chemistry</i> , 2013, 59, 1761-1769.	1.5	30
102	Multisite Analytical Evaluation of the Abbott ARCHITECT Cyclosporine Assay. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 145-151.	1.0	30
103	Post-mortem redistribution of three beta-blockers in the rabbit. <i>International Journal of Legal Medicine</i> , 2006, 120, 226-232.	1.2	29
104	Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 463-472.	1.0	29
105	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. <i>Transplantation</i> , 2016, 100, 640-647.	0.5	29
106	Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 428-433.	1.0	29
107	Patient Characteristics Influencing Cyclosporin Pharmacokinetics and Accurate Bayesian Estimation of Cyclosporin Exposure in Heart, Lung and Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 905-922.	1.6	28
108	Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 29-39.	1.6	28

#	ARTICLE	IF	CITATIONS
109	Low alfentanil target-concentrations improve hemodynamic and intubating conditions during induction with sevoflurane. <i>Canadian Journal of Anaesthesia</i> , 2004, 51, 382-387.	0.7	27
110	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 725-732.	0.7	27
111	Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 256-262.	0.7	27
112	Mycophenolic Acid Exposure Prediction Using Machine Learning. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 370-379.	2.3	27
113	Determination of Three β -Blockers in Biofluids and Solid Tissues by Liquid Chromatography-Electrospray-Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2004, 28, 674-679.	1.7	26
114	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016, 100, 2129-2137.	0.5	25
115	New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. <i>Pharmacogenomics</i> , 2016, 17, 277-296.	0.6	25
116	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 484-489.	1.3	25
117	Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. <i>Pharmacological Research</i> , 2017, 121, 138-144.	3.1	25
118	Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. <i>Pharmacological Research</i> , 2018, 129, 84-94.	3.1	25
119	Identification of Acepromazine in Hair: An Illustration of the Difficulties Encountered in Investigating Drug-facilitated Crimes. <i>Journal of Forensic Sciences</i> , 2008, 53, 755-759.	0.9	24
120	Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus. <i>Pharmacological Research</i> , 2021, 167, 105578.	3.1	24
121	Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. <i>Xenobiotica</i> , 2011, 41, 752-757.	0.5	23
122	Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 218-227.	1.6	23
123	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 285-291.	1.0	23
124	Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets?. <i>Pharmacological Research</i> , 2018, 129, 34-43.	3.1	23
125	A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3096-3106.	0.4	22
126	Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. <i>Pharmacological Research</i> , 2015, 99, 308-315.	3.1	22

#	ARTICLE	IF	CITATIONS
127	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. <i>Pharmacological Research</i> , 2011, 63, 432-438.	3.1	21
128	Fully automated sample preparation procedure to measure drugs of abuse in plasma by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 5071-5083.	1.9	21
129	The Key Role of Warm and Cold Ischemia in Uterus Transplantation: A Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 760.	1.0	21
130	LC-MS vs. GC-MS, Online Extraction Systems, Advantages of Technology for Drug Screening Assays. <i>Methods in Molecular Biology</i> , 2012, 902, 15-27.	0.4	19
131	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. <i>Pharmacological Research</i> , 2016, 111, 501-508.	3.1	19
132	Effects of Ischemia-Reperfusion on Tubular Cell Membrane Transporters and Consequences in Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 2610.	1.0	19
133	Development and Evaluation of a Simulation Procedure to Take Into Account Various Assays for the Bayesian Dose Adjustment of Tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 171-177.	1.0	18
134	How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. <i>Pharmacological Research</i> , 2015, 100, 281-287.	3.1	18
135	A Machine Learning Approach to Predict Interdose Vancomycin Exposure. <i>Pharmaceutical Research</i> , 2022, 39, 721-731.	1.7	18
136	Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 374-381.	1.0	17
137	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2012, 427, 52-59.	1.1	17
138	Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2793-2823.	1.1	17
139	Ingestion of High-Dose Buprenorphine by a 4 Year-Old Child. <i>Journal of Toxicology: Clinical Toxicology</i> , 2004, 42, 993-995.	1.5	16
140	Clinical Application of Population Pharmacokinetic Methods Developed for Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 727-732.	1.0	16
141	General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. <i>Journal of Separation Science</i> , 2009, 32, 2209-2217.	1.3	16
142	Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 836-846.	1.1	16
143	Tacrolimus Pharmacodynamics and Pharmacogenetics along the Calcineurin Pathway in Human Lymphocytes. <i>Clinical Chemistry</i> , 2014, 60, 1336-1345.	1.5	16
144	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , 2016, 8, 1343.	0.8	16

#	ARTICLE	IF	CITATIONS
145	Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1740-1750.	1.1	16
146	Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial. <i>Transplantation</i> , 2010, 89, 1255-1262.	0.5	15
147	An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies. <i>PLoS ONE</i> , 2017, 12, e0180236.	1.1	15
148	Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. <i>Digestive and Liver Disease</i> , 2011, 43, 850-855.	0.4	14
149	Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC). <i>Journal of Proteomics</i> , 2012, 75, 3674-3687.	1.2	14
150	Ciclosporin Population Pharmacokinetics and Bayesian Estimation in Thoracic Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 277-288.	1.6	14
151	Calcineurin Activity Assay Measurement by Liquid Chromatography-Tandem Mass Spectrometry in the Multiple Reaction Monitoring Mode. <i>Clinical Chemistry</i> , 2014, 60, 353-360.	1.5	14
152	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus. <i>Transplantation</i> , 2016, 100, 1705-1713.	0.5	14
153	Analytical Aspects of Volatile Substance Abuse (VSA). <i>Journal of Forensic Sciences</i> , 2003, 48, 1-3.	0.9	14
154	Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1018-1028.	1.3	14
155	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. <i>Pharmacological Research</i> , 2010, 61, 167-174.	3.1	13
156	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. <i>Pharmacogenomics</i> , 2016, 17, 375-391.	0.6	13
157	A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1157-1165.	1.6	13
158	Counterpoint: Is Pharmacokinetic or Pharmacodynamic Monitoring of Calcineurin Inhibition Therapy Necessary?. <i>Clinical Chemistry</i> , 2010, 56, 736-739.	1.5	12
159	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 145-156.	1.0	12
160	A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. <i>American Journal of Transplantation</i> , 2018, 18, 2905-2913.	2.6	12
161	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1459-1469.	1.6	12
162	Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 233-276.	2.3	12

#	ARTICLE	IF	CITATIONS
163	An Animal Model for the Study of Chronopharmacokinetics of Drugs and Application to Methotrexate and Vinorelbine. <i>Toxicology and Applied Pharmacology</i> , 2002, 183, 189-197.	1.3	11
164	Influence of Sampling-Time Error on Cyclosporine Measurements Nominally at 2 Hours after Administration. <i>Clinical Chemistry</i> , 2003, 49, 813-815.	1.5	11
165	Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 443-450.	1.0	11
166	The European Association for Clinical Pharmacology and Therapeuticsâ€™25Âyearsâ€™™ young and going strong. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 743-750.	0.8	11
167	Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 3449-3456.	1.9	10
168	Pharmacodynamic Monitoring of mTOR Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 160-167.	1.0	10
169	A Machine Learning Approach to Estimate the Glomerular Filtration Rate in Intensive Care Unit Patients Based on Plasma Iohexol Concentrations and Covariates. <i>Clinical Pharmacokinetics</i> , 2021, 60, 223-233.	1.6	10
170	Stability of Ribavirin Concentrations Depending on the Type of Blood Collection Tube and Preanalytical Conditions. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 237-241.	1.0	10
171	Thyroid Accumulation and Adverse Effects of Imipramine and Desipramine in Rats after Long-Term Administration. <i>Pharmacology</i> , 1998, 57, 242-248.	0.9	9
172	Translational Research: Precision Medicine, Personalized Medicine, Targeted Therapies: Marketing or Science?. <i>Therapie</i> , 2015, 70, 11-19.	0.6	9
173	Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters. <i>Medicine (United States)</i> , 2017, 96, e6469.	0.4	9
174	Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1550-1559.	1.1	9
175	Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 611-622.	1.6	9
176	Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. <i>Kidney International</i> , 2022, 102, 183-195.	2.6	9
177	Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. <i>Pediatric Nephrology</i> , 2009, 24, 395-402.	0.9	8
178	Case Study of Neonates Born to Mothers Undergoing Buprenorphine Maintenance Treatment. , 0, , 125-136.		8
179	Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies. <i>Frontiers in Immunology</i> , 2021, 12, 738795.	2.2	8
180	Immunosuppressant quantification in intravenous microdialysateÂ€ towards novel quasi-continuous therapeutic drug monitoring in transplanted patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 935-945.	1.4	8

#	ARTICLE	IF	CITATIONS
181	Ribavirin therapeutic drug monitoring: why, when and how?. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 401-406.	1.0	7
182	Ribavirin in chronic hepatitis C: past and future. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 249-253.	2.0	7
183	Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 451-456.	1.0	7
184	Letter to the Editor: ESI-MS ² library of 1,253 compounds for application in forensic and clinical toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 1947-1947.	1.9	7
185	Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3105-3114.	1.1	7
186	Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 472-480.	1.0	7
187	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial. <i>Transplantation Direct</i> , 2022, 8, e1316.	0.8	7
188	IN VITRO STUDY OF MYCOPHENOLIC ACID GLUCURONIDATION. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1524-1524.	1.7	6
189	Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. <i>BMC Cancer</i> , 2017, 17, 901.	1.1	6
190	Metabolic alterations of uterine grafts after extended cold ischemic storage: experimental study in ewes. <i>Molecular Human Reproduction</i> , 2019, 25, 647-659.	1.3	6
191	Pharmacology of High-Dose Buprenorphine. , 0, , 01-12.		6
192	Acylglucuronide in alkaline conditions: migration vs. hydrolysis. <i>Journal of Molecular Modeling</i> , 2013, 19, 2423-2432.	0.8	5
193	Overview of accessibility and quality of antiepileptic drugs in Madagascar. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016, 41, 134-140.	0.9	5
194	Activity of the Calcineurin Pathway in Patients on the Liver Transplantation Waiting List: Factors of Variability and Response to Tacrolimus Inhibition. <i>Clinical Chemistry</i> , 2017, 63, 1734-1744.	1.5	5
195	Comment on "Population Pharmacokinetics of Mycophenolic Acid: An Update". <i>Clinical Pharmacokinetics</i> , 2018, 57, 1211-1213.	1.6	5
196	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1449-1462.	1.6	5
197	Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 91-96.	1.0	4
198	Consensus Conference on a Composite Endpoint for Clinical Trials on Immunosuppressive Drugs in Lung Transplantation. <i>Transplantation</i> , 2014, 98, 1331-1338.	0.5	4

#	ARTICLE	IF	CITATIONS
199	First-Line Toxicological Screening with Fully Automated Extraction. <i>Journal of Analytical Toxicology</i> , 2021, 45, 252-268.	1.7	4
200	Fatal Intoxications with Chloral Hydrate. <i>Journal of Forensic Sciences</i> , 2001, 46, 1507-1509.	0.9	4
201	Pretransplantation calcineurin activity: towards individualized therapy?. <i>Liver International</i> , 2009, 29, 1454-1456.	1.9	3
202	Untargeted screening of urinary peptides with liquid chromatography coupled to hybrid linear-ion trap tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2012, 1259, 138-147.	1.8	3
203	Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients. <i>Progress in Transplantation</i> , 2019, 29, 300-308.	0.4	3
204	Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1179-1187.	1.0	3
205	A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
206	Modelling Ciclosporin Double-Peak Absorption Profiles in the Early Post-Transplantation Period. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1055-1057.	1.6	2
207	Pelvic magnetic resonance imaging in the ewe: A model for experimental gynecologic research. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 133-138.	0.6	2
208	Uterus human leucocyte antigen expression in the perspective of transplantation. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 1789-1795.	0.6	2
209	Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 684-692.	1.0	2
210	Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. <i>Pharmaceutical Medicine</i> , 2017, 31, 455-465.	1.0	2
211	The apoptosis-inducing toxin brefeldin A is taken up and secondarily released by neurons. <i>Neuroscience Research Communications</i> , 2000, 27, 125-133.	0.2	1
212	Letter to the Editor. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 138.	1.0	1
213	LC-MS/MS Screen for Xenobiotics and Metabolites. <i>Methods in Molecular Biology</i> , 2012, 902, 129-138.	0.4	1
214	Untargeted Screening of Urinary Peptides Using Offline Nano-Liquid Chromatography: MALDI-TOF/TOF Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2017, 1788, 113-121.	0.4	1
215	Pharmacology of Opiates During Pregnancy and in Neonates. , 0, , 119-124.		1
216	Reply:. <i>Hepatology</i> , 2008, 48, 693-694.	3.6	0

#	ARTICLE	IF	CITATIONS
217	Professor Folke Sjöqvist peacefully passed away on March 30, 2020. European Journal of Clinical Pharmacology, 2020, 76, 1477-1478.	0.8	0
218	How has the future investment program stimulated research and innovation in health?. Therapie, 2022, 77, 19-19.	0.6	0
219	Population Pharmacokinetics And Bayesian Estimation of Mycophenolate Mofetil In Patients With Autoimmune Hepatitis. British Journal of Clinical Pharmacology, 2022, , .	1.1	0